To summarize ECS-related therapeutic potential, it is suggested that moderate activation of CB1Rs by selective agonists or by endocannabinoids, as well as the elevation of eCB levels by inhibition of degrading enzymes MAGL or FAAH, may have acute beneficial therapeutic actions such as pain relief and antipsychotic effects, beneficial outcomes in some neuropsychiatric diseases, and potential beneficial effects in hypertension by a CB1R-dependent vasodilatory effect. Here, CNR1 is linked to Hypertension.